PT-141 (Bremelanotide) in Adults 65 and Older: Off-Label Use, Safety, and Clinical Guidance

What Is PT-141 and Why Is It Used Off-Label in Older Adults?

Bremelanotide works at melanocortin receptors in the central nervous system, not on vascular smooth muscle the way phosphodiesterase-5 inhibitors do. This central mechanism attracted clinicians hoping to address desire-phase dysfunction common in older men and women. The FDA approved the 1.75 mg auto-injector (Vyleesi) in June 2019 specifically for premenopausal women diagnosed with acquired, generalized HSDD, as documented in the FDA prescribing information for bremelanotide [1].

Geriatric patients were largely excluded from the phase 3 trials that supported approval. Sexual dysfunction remains clinically significant in older adults. A nationally representative survey published in JAMA Internal Medicine found that 43% of women and 31% of men between ages 57 and 85 reported at least one bothersome sexual problem [2]. That unmet need drives off-label interest.

The Melanocortin Pathway in Aging

The melanocortin system undergoes measurable change with age. MC4R density in hypothalamic nuclei declines in rodent models of aging, and human post-mortem data suggest parallel reductions in receptor expression [3]. Whether this means older patients require higher doses to achieve equivalent central stimulation, or that blunted receptor density protects against overstimulation, remains unresolved.

Why Physicians Consider It Despite No Approval

Age-related HSDD and male hypoactive sexual desire disorder (MHSDD) respond poorly to testosterone replacement alone in many patients. A 2021 review in the Journal of Sexual Medicine noted that testosterone improved desire in older men primarily when baseline levels were below 300 ng/dL, leaving a significant subset of eugonadal older men with persistent desire-phase complaints unaddressed [4]. Bremelanotide's central mechanism offers a theoretically complementary target.

Pharmacokinetics in Older Adults: What Changes With Age

No dedicated geriatric pharmacokinetic study for bremelanotide has been published to date. Extrapolation from general aging pharmacology is necessary, and that extrapolation signals meaningful exposure increases.

Renal Function Decline and Drug Exposure

The FDA label reports that severe renal impairment (creatinine clearance <30 mL/min) increases bremelanotide area under the curve (AUC) by approximately 70% compared with normal renal function [1]. Among adults 65 and older, roughly 30% have an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m², classifying them in CKD stage 3 or worse, based on NHANES data analyzed in JASN [5]. A 70% AUC increase translates directly into prolonged and intensified hemodynamic effects.

Hepatic Clearance and Protein Binding

Hepatic blood flow decreases by roughly 40% between age 25 and age 75, and cytochrome P450 activity declines in parallel [6]. Bremelanotide undergoes hydrolysis of its amide bonds rather than extensive CYP-mediated metabolism, which slightly limits this concern. Still, the net effect of reduced hepatic blood flow on peptide clearance in older adults is unknown because no trial has characterized it.

Volume of Distribution Shifts

Body composition changes in older adults, with decreased lean mass and increased adipose proportion, alter the volume of distribution for many peptide drugs. These changes may modestly prolong half-life. The published half-life for bremelanotide is approximately 2.7 hours in the studied (primarily premenopausal female) population [1].

Cardiovascular Safety: The Central Concern for Geriatric Patients

Bremelanotide reliably produces a transient decrease in blood pressure followed by a compensatory increase in heart rate after injection. The FDA label specifies that mean maximum blood pressure decreases of approximately 6 mmHg systolic and 4 mmHg diastolic occur within 12 hours of dosing [1].

This hemodynamic profile is manageable in a healthy 35-year-old. In a 70-year-old with impaired baroreflex sensitivity, orthostatic hypotension, or concurrent antihypertensive therapy, the same drop carries meaningfully greater risk. A systematic review of orthostatic hypotension in older adults published in JAMA found a prevalence of 20 to 30% in community-dwelling adults over 65, rising to 50% or more in nursing home residents [7].

Contraindication Language in the FDA Label

The FDA label states bremelanotide is contraindicated in patients with "known cardiovascular disease" and specifies it should not be used within 2 hours of nitrate administration [1]. Geriatric patients carry a disproportionate burden of coronary artery disease, heart failure, and hypertension. The AHA/ACC cardiovascular risk guidelines classify most adults over 65 as high or very high cardiovascular risk without additional risk factors simply based on age [8].

Blood Pressure Monitoring Protocol

Clinicians prescribing bremelanotide off-label to older adults typically recommend:

• Baseline sitting and standing blood pressure documented before the first dose
• A supervised first-dose observation with blood pressure checks at 30, 60, and 120 minutes
• Discontinuation if systolic blood pressure falls below 90 mmHg or the patient becomes symptomatic

No randomized trial has validated this monitoring protocol in patients 65 and older. It reflects consensus-based clinical caution rather than direct evidence.

Dosing Considerations for Geriatric Patients

The approved adult dose of bremelanotide is 1.75 mg by subcutaneous injection approximately 45 minutes before anticipated sexual activity. A maximum of one dose per 24-hour period applies. The FDA label carries no specific geriatric dosing recommendation and states that insufficient data exist to determine whether older patients require dose adjustment [1].

The Case for Starting at a Lower Dose

Given the pharmacokinetic arguments above, many clinicians experienced in peptide medicine start geriatric patients at 0.75 mg or 1.0 mg and titrate upward only if the response is inadequate and hemodynamic tolerance is confirmed. This approach mirrors the general geriatric prescribing principle of "start low, go slow," documented across multiple drug classes in the Beers Criteria published by the American Geriatrics Society [9].

A practical geriatric titration framework used in the HealthRX clinical workflow is as follows:

Step 1. Obtain complete cardiovascular history, resting ECG, and renal function panel. Step 2. If eGFR is <30 mL/min/1.73 m², do not initiate bremelanotide. Step 3. If eGFR is 30 to 59 mL/min/1.73 m², consider maximum dose of 1.0 mg and document informed consent for off-label, renally-adjusted use. Step 4. Begin at 0.75 mg for the first two administrations under blood pressure observation. Step 5. Advance to 1.0 mg if systolic blood pressure remains above 100 mmHg at nadir and no symptomatic hypotension occurs. Step 6. Do not advance beyond 1.75 mg in any patient 65 or older without specialist cardiology clearance.

Drug Interactions Common in Older Patients

Polypharmacy is nearly universal in adults 65 and older. A CDC analysis found that 36% of adults 65 and older used five or more prescription medications simultaneously [10]. Several drug classes relevant to this population interact with bremelanotide:

• Antihypertensives (beta-blockers, ACE inhibitors, calcium-channel blockers): additive blood pressure reduction
• Alpha-blockers used for benign prostatic hyperplasia (tamsulosin, alfuzosin): synergistic orthostatic hypotension risk
• Nitrates (nitroglycerin, isosorbide): absolute contraindication per FDA label [1]
• Opioids or CNS depressants: may blunt autonomic compensatory responses to blood pressure drops

Clinical Evidence: What the Trials Actually Enrolled

The two key phase 3 trials supporting bremelanotide's FDA approval, RECONNECT-1 and RECONNECT-2 (combined N=1,267 premenopausal women), enrolled women with a mean age of approximately 36 years [11]. Neither trial reported a subgroup analysis for women over 50, let alone 65. The 2019 approval was based exclusively on efficacy in this younger premenopausal cohort.

Male HSDD Trials

Bremelanotide's development program originally included studies in men with erectile dysfunction and male HSDD. An early phase 2 dose-finding study (N=98 men, mean age approximately 54 years) demonstrated improvements in erectile function scores but was not designed to isolate desire outcomes [12]. No published trial has enrolled men or women with a median or mean age at or above 65 as a primary population.

What the Evidence Does and Does Not Support

The efficacy signal for bremelanotide in younger premenopausal women with HSDD is well-established. RECONNECT-1 and RECONNECT-2 together showed statistically significant improvements in the Female Sexual Function Index desire domain and decreases in distress scores vs. Placebo (P<0.001 for both primary endpoints) [11]. Extrapolating these findings to a 70-year-old postmenopausal woman or a 72-year-old man requires the clinician to accept that the central melanocortin mechanism works similarly across four decades of biological aging, altered hormonal milieu, different comorbidity burden, and different neuroreceptor density. That extrapolation has not been validated.

Hormonal Context: Bremelanotide Alongside TRT and HRT in Older Adults

Most geriatric patients considered for bremelanotide have already undergone evaluation for hormone deficiency as a cause of their sexual dysfunction. Testosterone therapy in older men with confirmed hypogonadism (total testosterone <300 ng/dL on two morning draws) is supported by the Endocrine Society Clinical Practice Guidelines [13]. Estrogen-based HRT in postmenopausal women addressing genitourinary syndrome and related desire complaints carries its own evidence base from the NAMS 2022 Hormone Therapy Position Statement [14].

When Bremelanotide Might Add Value

Some patients on optimized TRT or HRT continue to report desire-phase dysfunction rather than arousal or orgasmic dysfunction. This residual desire deficit is the plausible niche for bremelanotide in older adults, targeting the central desire circuit while hormone optimization addresses the peripheral and metabolic contributors. No head-to-head trial has compared combined bremelanotide-plus-TRT against TRT alone in any age group.

Estrogen Deficiency and MC4R Sensitivity

Animal data suggest estrogen may upregulate hypothalamic MC4R expression, implying postmenopausal women could have reduced bremelanotide responsiveness compared with premenopausal women [3]. If confirmed in humans, this would further complicate efficacy extrapolation to older female patients. A 2022 review in Neuroendocrinology examined melanocortin-sex hormone crosstalk and noted that "estrogen status appears to modulate the sensitivity of MC4R-mediated behavioral responses in rodent models, with implications for human therapeutic translation" [15].

Nausea, Flushing, and Other Adverse Effects in the Geriatric Context

In the RECONNECT trials, nausea occurred in 40.1% of bremelanotide recipients vs. 1.3% of placebo recipients [11]. Flushing affected 20.3%, and injection-site reactions occurred in 15.0%. Hyperpigmentation of the face and breasts was observed with repeat dosing, attributed to off-target MC1R and MC3R activation [1].

Nausea in older adults carries specific consequences that differ from those in younger populations. Aspiration risk is higher in patients with any degree of esophageal dysmotility or impaired gag reflex. Severe nausea combined with blood pressure reduction can precipitate syncope. Clinicians should prescribe an antiemetic (ondansetron 4 mg orally 30 minutes before injection is commonly used in practice) and document the plan in the medical record.

Informed Consent and Documentation for Off-Label Prescribing

Off-label prescribing is legal in the United States and accounts for approximately 20% of all outpatient prescriptions according to an analysis in Archives of Internal Medicine [16]. Prescribing bremelanotide to an adult 65 or older requires thorough informed consent documentation because:

1. No efficacy evidence exists specifically in this age group.
2. The hemodynamic adverse-effect profile carries greater clinical consequence in older patients.
3. Insurance will not cover off-label prescribing, creating a cost burden.
4. Compounded bremelanotide products sold outside of pharmacy channels are not FDA-reviewed for purity or concentration.

The FDA guidance on off-label drug use clarifies the legal framework for physicians [17]. Documentation should include the clinical rationale, the discussion of alternatives, the absence of evidence in the target age group, and the patient's understanding of these limitations.

Practical Checklist Before Prescribing Bremelanotide Off-Label in a Patient 65 or Older

Before initiating therapy, a prescribing clinician should confirm the following:

• Diagnosis of HSDD or MHSDD established by validated instrument (Female Sexual Distress Scale-Revised or equivalent)
• Cardiovascular risk assessment completed; high-risk patients excluded
• Resting ECG reviewed; no evidence of significant arrhythmia or conduction delay
• Renal function panel obtained; eGFR <30 mL/min/1.73 m² is a hard stop
• Full medication reconciliation completed; nitrates, alpha-blockers identified and managed
• Hormone levels reviewed; untreated hypogonadism or severe estrogen deficiency addressed first
• Patient counseled on nausea mitigation, blood pressure self-monitoring, and orthostatic precautions
• Informed consent for off-label use documented in the chart

A 2023 position paper from the International Society for Sexual Medicine noted that "the evidence base for pharmacological management of desire disorders in older adults remains critically underdeveloped, and clinicians must balance therapeutic intent against individualized risk in the absence of age-specific trial data" [18].